CJC-1295 with DAC trial reference

Confirm the molecule

This entry covers CJC-1295 with drug affinity complex, or DAC. MOD GRF 1-29 and products called CJC-1295 no-DAC are outside this entry. They are not interchangeable names for the molecule tested here. FDA treats DAC-containing and non-DAC forms as distinct active moieties. The published human reports did not specify the salt form.

What the early trials measured

Teichman and colleagues reported two randomized, double-blind, placebo-controlled trials lasting 28 and 49 days in healthy adults aged 21 to 61. They tested single and repeated subcutaneous injections. Repeat injections used weekly or every-other-week spacing within the research protocol. This describes study design, not an established treatment schedule.

GH and IGF-1 increased. These are biomarker findings. The trials did not demonstrate fat loss, improved strength, better sleep, or longer life. No CJC-1295 product has FDA approval as of November 6, 2026. Limited short-term observations cannot establish long-term safety. FDA also reports safety concerns for compounded CJC-1295.

Record identity and purpose

For a clinician-directed discussion, record the exact molecule, DAC status, salt if known, product source, route, and the clinician-documented purpose and schedule. Keep actual administration dates, symptoms, and clinician-requested laboratory results together. An unclear product identity belongs in the record as unknown. A hormone change alone does not show that a health goal was reached.